Abstract
Introduction: The aim of the study was to evaluate the concentration of 9a11b prostaglandin F2, a stable metabolite of prostaglandin D2 (PGD2) and leukotriene E4 (LTE4), in patients with stable and exacerbated chronic obstructive pulmonary disease (COPD). Material and methods: The study included 29 COPD patients aged 73 ± 8.34 years, with mean FEV1 = 48.64 ± 15.75% of predicted normal value, and 29 healthy controls aged 57.48 ± 10.86 years, with mean FEV1 = 97.17 ± 13.81% of predicted normal value. Urine and blood samples were taken from COPD patients during exacerbation and in the stable phase of the disease; LTE4 was measured in urine using commercial enzyme immunoassay (EIA), and 9a11b prostaglandin F2 (9a11bPGF2), a stable metabolite of PGD2, was measured in blood and urine using GC/MS. Results: Urine concentrations of LTE4 in urine (677.15 vs. 436.4 pg/mg of creatinine; p = 0.035) and serum levels of 9a11bPGF2 (5.35 vs. 3.07 pg/mL; p = 0.007) were significantly higher in patients with exacerbated COPD than in the control group. There was no difference in LTE4 levels in urine and 9a11bPGF2 in serum between exacerbated and stable COPD. The urinary 9a11bPGF2 concentration did not differ between the studied groups. We found a positive correlation between smoking history and urine LTE4 level (r = 0.395; p = 0.002) as well as blood 9a11bPGF2 concentration (r = 0.603; p = 0.001) in COPD patients. Conclusions: Urine levels of 9a11bPGF2 and LTE4 did not differ between the stable COPD group and the control group. There were no differences between urine LTE4 levels and blood and urine 9a11bPGF2 levels between exacerbated and stable COPD. Finally, LTE4 concentration in urine and 9a11bPGF2 in blood were significantly higher in exacerbated COPD patients than in the control group.